Dan Montano
Daniel Montano is the CEO of Zhittya Genesis Medicine Inc. For the last 21 years, he has been advancing a group of biological drugs which in USA FDA clinical trials has demonstrated that it triggers the growth of new blood vessels in ischemic tissues, a medical treatment we call "Therapeutic Angiogenesis". He believes their drug treatment (if and when approved by the USA FDA) can treat the cause of death and suffering which affects over 50% of the adults in the world. He has expended over $140 million, so far advancing this medicine through research and clinical trials to seek regulatory approval. Presently we are advancing 19 medical indications.
